Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 6, 2007

View Archived Issues

Neuren to acquire Hamilton

TargeGen begins phase II trial of TG-100801 eye drops for AMD

Positive results for Novogen's antiinflammatory FAIMs in preclinical studies

Lexicon completes phase I trials of LX-6171 for cognitive disorders

AVEO's oral antiangiogenic agent heads for phase II evaluation in RCC

Phase II study data on vicriviroc presented

Sanofi-aventis and Chugai marketing collaboration in Japan terminated

New treatment options for cardiovascular diseases discussed in recent patent literature

New compounds for the treatment of neurological disorders claimed in recent patents

New antiarthritic drugs claimed in recent patent literature

Positive interim results from AlphaVax's phase I influenza vaccine trial

Astion's ASF-1096 recommended orphan drug status by EMEA

Kyowa Hakko receives MHLW approval for antiepileptic agent KW-6485

Banyu receives MHLW approval for Singulair fine granule 4 mg for infant bronchial asthma

Incyte reports second quarter 2007 results

FDA accepts Fentanyl MDTS IND from Acrux; phase I trial to begin

Poniard begins phase II trial of intravenous picoplatin with Taxotere and prednisone

Javelin begins phase III trial of intranasal ketamine for breakthrough cancer pain

Phase II trial of trastuzumab-DM1 begins; ImmunoGen receives milestone payment

AlphaVax proceeds with the development of a smallpox vaccine

Inactivated whole-virion SARS vaccine immunogenic and protective in hamster model

Erythropoietin modulates emotional responses in humans

Accentia submits pre-IND application for Revimmune

YM begins enrollment of phase II trial of nimotuzumab for colorectal cancer

Positive interim results for OncoGenex and Isis' phase II OGX-011 trial

Antigenics applies for Oncophage approval for kidney cancer in Russia

Second FDA approvable letter issued for Trexima

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 19, 2026.
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
ADPD 2026: Can we prevent dementia? Scientists quantify it
BioWorld
Neurodegenerative disease and cognitive decline cannot be explained by a single process. Beta-amyloid plaques, hyperphosphorylated tau, alpha-synuclein, activated...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...